GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anthem Biosciences Ltd

Anthem Biosciences Q1 FY27 Standalone Profit Declines to Rs. 1,020.09 Mn

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 04:36 PM IST  ·  BSE ID: 74a2e957-9d1c-4409-a91d-60413b38b096
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first-quarter financial results for FY27, showing a decrease in profit and revenue compared to the prior year.
🤖 AI Summary
  • Anthem Biosciences' Board approved Q1 FY27 standalone and consolidated financial results on July 21, 2026.
  • Standalone profit for the period ended June 30, 2026, was Rs. 1,020.09 Mn.
  • Standalone revenue from operations for Q1 FY27 stood at Rs. 3,838.42 Mn.
  • The company allotted 1,670,909 fully paid-up equity shares under its ESOP Scheme 2024.
  • Auditors issued an unmodified opinion on both standalone and consolidated financial results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations Q1 FY27
3,838.42 Mn
-28.65
Standalone Profit for the Period Q1 FY27
1,020.09 Mn
-31.37
Basic Earnings per Share Q1 FY27
1.81
-31.69
Equity Shares Allotted under ESOP
1,670,909 nos
🏢 How This Affects the Company
📈
Business Impact
Standalone revenue from operations for Q1 FY27 decreased to Rs. 3,838.42 Mn from Rs. 5,380.11 Mn in Q1 FY26.
💰
Financial Impact
Standalone profit for the period in Q1 FY27 was Rs. 1,020.09 Mn, a decrease of 31.37% compared to Rs. 1,483.40 Mn in Q1 FY26.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Existing shareholders are affected by the company's financial performance, specifically the decline in profit and revenue reported for Q1 FY27. Employee stock option holders benefit from the allotment of 1,670,909 new shares.
🔍
Management Signal
The approval of financial results indicates management's adherence to regulatory disclosure requirements and the continuation of employee incentive programs.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q2 FY27 financial results — check revenue and profit trends.
Details on future ESOP allotments and their impact on share capital.
Company disclosures on operational initiatives to address revenue decline.
MEDIUM RISK Decline in both standalone revenue and profit for the quarter compared to the prior year indicates business headwinds.
💡 Investor Takeaway
Anthem Biosciences' Q1 FY27 standalone profit declined 31.37% to Rs. 1,020.09 Mn from Rs. 1,483.40 Mn in Q1 FY26. Revenue from operations also decreased 28.65% to Rs. 3,838.42 Mn from Rs. 5,380.11 Mn YoY.
⚖️ Strengths & Concerns

✅ Positives

  • Auditors K. P. Rao & Co. issued an unmodified opinion on both the standalone and consolidated financial results for Q1 FY27.
  • The company's paid-up equity share capital increased to Rs. 1,126.77 Mn due to ESOP allotment, reflecting employee incentives.

⚠️ Concerns

  • Standalone revenue from operations decreased by 28.65% to Rs. 3,838.42 Mn in Q1 FY27 from Rs. 5,380.11 Mn in Q1 FY26.
  • Standalone profit for the period declined by 31.37% to Rs. 1,020.09 Mn in Q1 FY27 from Rs. 1,483.40 Mn in Q1 FY26.
📅 Company Track Record
Anthem Biosciences' Q1 FY27 standalone net profit decreased to Rs. 1,020.09 Mn. This follows previous filings indicating Q1 FY27 net profit decreases, including a consolidated net profit decline of 11.7% YoY to ₹1,199 Mn.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Anthem Biosciences' standalone profit for Q1 FY27?
Anthem Biosciences' standalone profit for the quarter ended June 30, 2026, was Rs. 1,020.09 Mn.
How did Anthem Biosciences' standalone revenue from operations perform in Q1 FY27?
Standalone revenue from operations for Anthem Biosciences in Q1 FY27 was Rs. 3,838.42 Mn, compared to Rs. 5,380.11 Mn in Q1 FY26.
What was the Basic Earnings per Share (EPS) for Anthem Biosciences in Q1 FY27?
Anthem Biosciences reported a Basic Earnings per Share of 1.81 for the quarter ended June 30, 2026.
How many equity shares did Anthem Biosciences allot under its ESOP Scheme 2024 in Q1 FY27?
Anthem Biosciences allotted 1,670,909 fully paid-up equity shares of Rs. 2 each under its ESOP Scheme 2024 during the quarter.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.